Expertspeak
Not all Covid-19 patients need antivirals. New drugs for restricted use at physicians’ discretion: Cipla Ltd and Hetero Drugs have got authorisations for antiviral remdesivir for restricted emergency use, and Glenmark Pharmaceuticals, has got an approval for manufacture and marketing antiviral favipiravir. These medicines are likely to be available in the hands of medical professionals who are fighting Covid-19. How do these medicines work? What do we know of them today as opposed to what we knew of them earlier and what they were used for? And how are they likely to help the treatment of Covid-19 patients? Read this interview with Rommel Tickoo, associate director, internal medicine, at Max Healthcare, New Delhi.
Managing Covid-19
Guwahati lockdown explained: Here are the guidelines till July 12: A total lockdown will come into force in Assam’s Kamrup Metropolitan district — which includes Guwahati city — from June 28, 7 pm till July 12, 6 pm. The new lockdown guidelines are more stringent than the earlier guidelines. In a press conference on Friday, State Health Minister Himanta Biswa Sarma said this was a “stringent lockdown”, and “almost like a curfew. Read more here
Looking beyond just a testing milestone: As Tamil Nadu notched up its first million Covid-19 tests, the first to reach the milestone in the country, data on the number of tests being done in its different labs — 47 in the government sector and 42 in the private sector — have been made available. Read more here
OPINION
How Ramdev’s Coronil makes social media’s fight against misinformation more difficult: The introduction of a ‘cure’ and the resulting reaction — the Narendra Modi government’s AYUSH Ministry has asked Patanjali to stop advertising Coronil, and the Uttarakhand Ayurveda Department has said the company did not mention ‘coronavirus’ in its application seeking licence — raises an important debate on information disorder on social media platforms. And the question of what medical misinformation constitutes during times of a pandemic and otherwise. Read more here
Understanding Covid-19
Long road to recovery for discharged patients: Many recovered patients have complained of loss of taste, loss of smell, body fatigue, body pain, low blood pressure, stroke, blood sugar fluctuation and cardiac problems — now common signs during convalescence. Doctors across the city said apart from treating actively infected Covid-19 patients, they also have to monitor patients discharged after treatment. Patients are taking 3-4 weeks to regain their sense of taste, and longer for the sense of smell to return. Read more here
A sensor for flu and Covid-19 at the same time; can tell difference: Covid-19 shares number of symptoms with the common flu. Researchers are now developing a new sensor that can tell the difference between the two illnesses — and test for both simultaneously. A dual test improves on current options in several ways. It’s more convenient for patients who wouldn’t have to get multiple tests done. It also saves time for medical personnel when resources are stretched. Read more
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)